Multimodal imaging with 18F-FDG-PET/CT and 111In-Octreotide SPECT in patients with metastatic medullary thyroid carcinoma

Luca, Stefania De; Fonti, Rosa; Camera, Luigi; Salvatore, Barbara; Faggiano, Antongiulio; Ciarmiello, Andrea; Segreto, Sabrina; Colao, Annamaria; Salvatore, Marco; Vecchio, Silvana Del

doi:10.1007/s12149-015-1056-5

Cited by 11 publications

(8 citation statements)

References 37 publications

(45 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Radionuclide therapy with radiolabelled somatostatin analogs (SSAs) is another effective theragnostic option in selected cases. The expression of somatostatin receptors has been demonstrated in vitro [ 131 ] and in vivo studies [ 132 ]. This represents the basis for PRRT, mainly performed with [ 177 Lu] and [ 90 Y] radiolabelled SSAs.…”

Section: Medullary Thyroid Cancermentioning

confidence: 99%

Molecular Imaging and Theragnostics of Thyroid Cancers

Giovanella

Deandreis

Vrachims³

et al. 2022

Cancers

View full text Add to dashboard Cite

Molecular imaging plays an important role in the evaluation and management of different thyroid cancer histotypes. The existing risk stratification models can be refined, by incorporation of tumor-specific molecular markers that have theranostic power, to optimize patient-specific (individualized) treatment decisions. Molecular imaging with varying radioisotopes of iodine (i.e., 131I, 123I, 124I) is an indispensable component of dynamic and theragnostic risk stratification of differentiated carcinoma (DTC) while [18F]F-fluorodeoxyglucose ([18F]FDG) positron emission tomography/computed tomography (PET/CT) helps in addressing disease aggressiveness, detects distant metastases, and risk-stratifies patients with radioiodine-refractory DTC, poorly differentiated and anaplastic thyroid cancers. For medullary thyroid cancer (MTC), a neuroendocrine tumor derived from thyroid C-cells, [18F]F-dihydroxyphenylalanine (6-[18F]FDOPA) PET/CT and/or [18F]FDG PET/CT can be used dependent on serum markers levels and kinetics. In addition to radioiodine therapy for DTC, some theragnostic approaches are promising for metastatic MTC as well. Moreover, new redifferentiation strategies are now available to restore uptake in radioiodine-refractory DTC while new theragnostic approaches showed promising preliminary results for advanced and aggressive forms of follicular-cell derived thyroid cancers (i.e., peptide receptor radiotherapy). In order to help clinicians put the role of molecular imaging into perspective, the appropriate role and emerging opportunities for molecular imaging and theragnostics in thyroid cancer are discussed in our present review.

show abstract

Section: Medullary Thyroid Cancermentioning

confidence: 99%

Molecular Imaging and Theragnostics of Thyroid Cancers

Giovanella

Deandreis

Vrachims³

et al. 2022

Cancers

View full text Add to dashboard Cite

show abstract

“…Its overall sensitivity ranges from 47% to 79% and its lesion-based sensitivity is even higher between 76% and 96% [ 46 ]. In metastatic MTC patients, 18F-FDG-PET/CT provides a useful contribution mainly in evaluating lymph node involvement whereas (111)In-Octreotide SPECT can contribute to the detection and somatostatin receptor characterization especially of bone lesions [ 61 ]. Another study also indicated that 18F-FDG PET is more sensitive than CT, MRI, and 131I-MIBG in localizing lymph node involvement in MTC patients with postsurgically elevated calcitonin levels [ 62 ].…”

Section: Nuclear Molecular Imaging In Medullarymentioning

confidence: 99%

Recent Development of Nuclear Molecular Imaging in Thyroid Cancer

Liu

Wang

Yang

et al. 2018

BioMed Research International

View full text Add to dashboard Cite

Therapies targeting specific tumor pathways are easy to enter the clinic. To monitor molecular changes, cellular processes, and tumor microenvironment, molecular imaging is becoming the key technology for personalized medicine because of its high efficacy and low side effects. Thyroid cancer is the most common endocrine malignancy, and its theranostic radioiodine has been widely used to diagnose or treat differentiated thyroid cancer. This article summarizes recent development of molecular imaging in thyroid cancer, which may accelerate the development of personalized thyroid cancer therapy.

show abstract

“…De Luca et al (18) have retrospectively analyzed metastatic medullary thyroid cancer patients who had undergone 18 F-FDG PET/CT. They concluded that 18 F-FDG PET/CT was primarily useful in lymph node involvement evaluation.…”

Section: Medullary Thyroid Cancermentioning

confidence: 99%

“…They concluded that 18 F-FDG PET/CT was primarily useful in lymph node involvement evaluation. Lung, liver or brain metastases could be missed due to the small size or low metabolic activity and as for skeletal metastases, detectability was limited to lytic metastases (18). …”

Section: Medullary Thyroid Cancermentioning

confidence: 99%

18F-Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography for Other Thyroid Cancers: Medullary, Anaplastic, Lymphoma and So Forth

Araz

Çayir²

2017

Mirt

View full text Add to dashboard Cite

Positron emission tomography/computed tomography (PET/CT) with 18F-fluorodeoxyglucose (FDG) is used in staging, restaging, and evaluation of therapy response in many cancers as well as differentiated thyroid carcinomas especially in non-iodine avid variants. Its potential in less frequent thyroid tumors like medullary, anaplastic thyroid cancers, thyroid lymphoma and metastatic tumors of the thyroid however, is not well established yet. The aim of this review is to provide an overview on the recent applications and indications of 18F-FDG PET/CT in these tumors and to focus on the controversies in the clinical setting.

show abstract

Multimodal imaging with 18F-FDG-PET/CT and 111In-Octreotide SPECT in patients with metastatic medullary thyroid carcinoma

Abstract: In MMTC patients, (18)F-FDG-PET/CT provides a useful contribution mainly in evaluating lymph node involvement whereas (111)In-Octreotide SPECT can contribute to the detection and somatostatin receptor characterization especially of bone lesions.

Cited by 11 publications

References 37 publications

Molecular Imaging and Theragnostics of Thyroid Cancers

Molecular Imaging and Theragnostics of Thyroid Cancers

Recent Development of Nuclear Molecular Imaging in Thyroid Cancer

18F-Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography for Other Thyroid Cancers: Medullary, Anaplastic, Lymphoma and So Forth

Contact Info

Product

Resources

About